Inspire Medical Systems (INSP) Projected to Announce Quarterly Earnings on Monday

Inspire Medical Systems (NYSE:INSP) is projected to issue its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of $0.0870 per share and revenue of $204.31 million for the quarter. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.45 earnings per share. On average, analysts expect Inspire Medical Systems to post $1.24 EPS for the current fiscal year and $1.54 EPS for the next fiscal year.

Inspire Medical Systems Stock Down 4.4%

NYSE:INSP opened at $68.02 on Friday. The company has a market cap of $1.97 billion, a P/E ratio of 14.72, a P/E/G ratio of 5.15 and a beta of 0.73. The firm’s 50 day moving average is $68.59 and its two-hundred day moving average is $58.94. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03.

Insider Transactions at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on INSP shares. Barclays initiated coverage on shares of Inspire Medical Systems in a research note on Tuesday, October 6th. They set an “underweight” rating and a $65.00 price objective for the company. Royal Bank Of Canada increased their target price on Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 1st. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Oppenheimer upgraded Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a report on Tuesday, August 4th. Finally, Piper Sandler boosted their price target on Inspire Medical Systems from $55.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $68.82.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.